- Home
- AXL vs PSNL Comparison
AXL vs PSNL Comparison
Compare AXL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXL | PSNL |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 795.3M | 746.8M |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AXL | PSNL |
|---|---|---|
| Price | $7.82 | $9.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $7.31 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 02-13-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $5,833,600,000.00 | $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.66 | $20.33 |
| P/E Ratio | $22.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $2.83 |
| 52 Week High | $7.92 | $11.40 |
Technical Indicators
Market Signals| Indicator | AXL | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 72.89 | 60.28 |
| Support Level | $7.57 | $7.87 |
| Resistance Level | $7.85 | $9.74 |
| Average True Range (ATR) | 0.29 | 0.58 |
| MACD | 0.12 | 0.16 |
| Stochastic Oscillator | 93.40 | 96.76 |
Price Performance
Historical ComparisonAbout AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.